1st International AIDS Conference Atlanta, Georgia, U.S.A. - April 14-17, 1985

Int Conf AIDS. 1985 Apr 14-17;1:25 (abstract no. S7A)

David Hardy, PR Wolfe, MS Gottlieb, S Knight, R Mitsuyasu, LS Young
University California, Los Angeles

PCP is the most frequently occurring opportunistic infection in patients with the Acquired Immunodeficiency Syndrome (AIDS). Most patients respond to co-trimoxazole (CTM) and/or pentamidine therapy during the initial episode. Relapses of PCP in non-prophylaxed patients are common (30-50%). Adverse reactions to CTM often complicate initial therapy and subsequent prophylaxis. For these reasons we have entered 29 patients with biopsy-proven PCP into a pilot study of Fansidar (pyrimethamine and sulfadoxine in a 1:20 ratio) for prophylaxis. Of 29 patients, 24 had had previous adverse reactions to CTM (14 with rash, 8 with leukopenia and 2 with GI intolerance). Following successful initial therapy all 29 patients were placed on Fansidar at a dose of one tablet q week or q 2 weeks PO. No patient has had a relapse of PCP while on Fansidar; 6 patients did relapse several weeks after it was stopped. 21 patients who had had previous adverse reactions to CTM tolerated Fansidar well. Fansidar was stopped in 5 of 29 patients because of skin rashes. Mean duration of Fansidar therapy was 6 months (range 1 to 20 months). We conclude that Fansidar is a safe and effective prophylactic agent against relapse of PCP.

Supported in part by a grant to the UCLA AIDS Center from the University of California Task Force on AIDS.

850414
S7A

Copyright © 1985 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.